PRODUCT SEARCH
Enquiries
If you have any questions about products featured on this site, or on products that you cannot find on this site, please contact us and we will be happy to assist you in any way that we can. We have a team of technical sales specialists who are waiting to hear from you!
Contact UsHome > Life Science Solutions > Cell Culture Media > Mammalian Cell Culture Production Media MAM-PF ®
Mammalian Cell Culture Production Media MAM-PF ®
BioConcept Ltd has been able to manufacture and supply a new form of Mammalian Cell Culture Media thanks to the breakthrough in recombinant protein production. MAM-PF® known as Mammalian Artificial Media is a line of media tailor made to satisfy the needs of large-scale therapeutics and biosimilars producers**. The Mammalian Cell Culture Media is Animal Component Free and is produced in accordance with EMA/410/01.
MAM-PF® Cell Culture Media is also protein-free, protein hydrolysates free and chemically defined. It can be used for high-density cell culture of a variety of cell lines, including CHO (Chinese Hamster Ovary) cells, and BHK (Baby Hamster Kidney) cells, as well as high-level recombinant proteins expression. BioConcept holds a certificate for each component used in the MAM-PF® media series, ensuring a clean and high-quality finished product.
Benefits of MAM-PF® Series:
Protein and protein hydrolysates free
Chemically Defined
Best glycosylation pattern can be observed
Easy to adapt from current medium to MAM-PF Medium
High-cell density combined with high product yield
Antibody product of up to 5.5 g/L
EPO of up to 2.5 g/L
Cell density of up to 3.7 x 10 to the power 7 cells/ml
Liquid batch capacity ranging from 5-10,000 litres
Powder batch capacity from 1 – 800 kg
Selection of pre-developed biosimilars produced with MAM-PF® media series:
|
API (Indication) |
Available (EUGENEX Biotechnologies) |
Brand Name (Orginator) |
|
EPO, Epoetin alpha (Anemia) |
Cell-Line & USP & DSP |
Epogen (Amgen) Eprex (Johnson) |
|
DPO, Darbepoetin alpha (Anemia) |
Cell-Line & USP & DSP |
Aranesp (Amgen) |
|
INFb, Interferon beta 1a (MS) |
Cell-Line & USP & DSP |
Avonex (Biogen) Rebif (Serono) |
|
FSH, follicle stimulating hormone (Infertility); also hCG & LH |
Cell-Line & USP & DSP |
Gonal-F (Serono) Puregon (Organon) |
|
Etanercept, TNFa receptor IgG (chronical arthritis, psoriasis) |
Cell Line USP & DSP |
Enbrel (Amgen, Pfizer, Takeda) |
|
Adalimumab, TNFa Mab (rheumatoid arthritis, Crohn’s) |
Cell Line USP & DSP |
Humira (Abbott) |
|
Rituximab, CD20 Mab (rheumatoid arthritis, lymphoma) |
Cell Line USP & DSP |
Rituxan (Roche) |
|
Trastuzumab, HER2 Mab (mammacarcinom) |
Cell Line USP & DSP |
Herceptin (Roche) |
|
Bevacizumab, VEGF Mab (colorectal cancer) |
Cell Line USP & DSP |
Avastin (Roche) |
|
Cetuximab, EGF receptor Mab (colorectal cancer) |
Cell Line USP |
Erbitux (BMS,Imclone) |
|
Omalizumab, IgE Mab (persistent allergic asthma) |
Cell Line USP |
Xolair (Genentech/Novartis) |
|
Denosumab, RANKL IgG (osteoporosis, colorectal cancer) |
Cell Line USP |
Prolia (Amgen) |
|
Eculizumab, Complement C5 Mab (hemoglobinuria (PNH)) |
Cell Line USP |
Soliris (Alexion) |
|
Ipilimumab, CTLA-4 IgG1 (metastatic melanoma) |
Cell Line USP |
Yervoy (BMS) |
|
Tocilizumab, IL-6R IgG1 (Castelman, rheumatoid arthritis) |
Cell Line |
Actemra (Roche, Chugai) |
|
Abatacept, CTLA-4-IgG1 fusion (rheumatoid arthritis) |
Cell Line |
Orencia (BMS) |
|
Pertuzumab, Her2 dimer inhibitor (metastatic breast cancer) |
Cell Line USP |
Omnitarg (Roche) |
|
Panitumumab, EGF-R Mab (colorectal cancer) |
Cell Line |
Vectibix (Genentech/Novartis) |
|
Ofatumumab, CD20 IgG1 2nd Gen. (leukemia and others) |
Cell Line |
Arzerra (Genmab/GSK) |
- Download MAM-PF Brochure